Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
Ash A. Alizadeh, Andrew J. Gentles, Alvaro Jose Alencar et al. · Blood · 2011
Several gene-expression signatures predict survival in diffuse large B-cell lymphoma (DLBCL), but the lack of practical methods for genome-scale analysis has limited translation to clinical practice. We built and validated a simple model using one gene expressed by tumor cells and another expressed by host immune cells, assessing added prognostic value to the clinical International Prognostic Index (IPI). LIM domain only 2 (LMO2) was validated as an independent predictor of survival and the "germinal center B cell-like" subtype. Expression of tumor necrosis factor receptor superfamily member 9 (TNFRSF9) from the DLBCL microenvironment was the best gene in bivariate combination with LMO2. Study of TNFRSF9 tissue expression in 95 patients with DLBCL showed expression limited to infiltrating T cells. A model integrating these 2 genes was independent of "cell-of-origin" classification, "stromal signatures," IPI, and added to the predictive power of the IPI. A composite score integrating these genes with IPI performed well in 3 independent cohorts of 545 DLBCL patients, as well as in a simple assay of routine formalin-fixed specimens from a new validation cohort of 147 patients with DLBCL. We conclude that the measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9) powerfully predicts overall survival in patients with DLBCL.
Cited by 200 works. doi:10.1182/blood-2011-03-345272
Authors
- Ash A. Alizadeh
- Andrew J. Gentles
- Alvaro Jose Alencar
- Chih Long Liu
- Holbrook E K Kohrt
- Roch Houot
- Matthew Jordan Goldstein
- Shuchun Zhao
- Yasodha Natkunam
- Ranjana H. Advani
- Randy D. Gascoyne
- Javier Briones
- Robert John Tibshirani
- June H. Myklebust
- Sylvia K. Plevritis
- Izidore S. Lossos
- Ronald Levy
References
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
- Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
- WHO classification of haematolymphoid tumours
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
- Treatment of Acute Lymphoblastic Leukemia
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte